The synthesis of a dopamine D2 partial agonist for the treatment of schizophrenia

Organic Process Research and Development

Volumn 13, Issue 3, 2009, Pages 555-566

  Magano, Javier ^a   Acciacca, Alison ^a   Akin, Anne ^a   Collman, Benjamin M ^a   Conway, Brian ^a   Waldo, Michael ^a   Chen, Michael H ^b   Mennen, Kenneth E ^c  

^a PFIZER INC   (United States)

^b Beijing PharmaSciences   (China)

^c ARRAY BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 66249132023     PISSN: 10836160     EISSN: 1520586X     Source Type: Journal    
DOI: 10.1021/op800307k     Document Type: Article

References (62)

1. Schultz, S. H.; North, S. W.; Shields, C. G. Am. Fam. Physician 2007, 75, 1821.
2. Jain, K. K. Exp. Opin. Invest. Drugs 2000, 9, 2935.
3. Gray, J. A.; Roth, B. L. Mol. Psychiatry 2007, 12, 904.
4. Vohora, D. Curr. Opin. Invest. Drugs 2007, 8, 531.
5. (a) Clark, J. D.; Davis, J. M.; Favor, D.; Fay, L. K.; Franklin, L.; Henegar, K. E.; Johnson, D. S.; Nichelson, B. J.; Ou, L.; Repine, J. T.; Walters, M. A.; White, A. D.; Zhu, Z. U.S. Pat. Appl. Publ. 20050043309 A1, 2005. CAN 142:261526.
6. Favor, D. A.; Johnson, D. S.; Repine, J. T.; White, A. D. PCT Int. Appl. WO 2006103559 A1, 2006. CAN 145:397556.
7. Chen, M. H. G.; Magano, J.; Mennen, K. E. PCT Int. Appl. WO 2007116265 A1, 2007. CAN 147:448819.
8. (a) Kaminski, J. J.; Perkins, D. G.; Frantz, J. D.; Solomon, D. M.; Elliott, A. J.; Chiu, P. J. S.; Long, J. F. J. Med. Chem. 1987, 30, 2047.
9. Ikemoto, T.; Kawamoto, T.; Wada, H.; Ishida, T.; Ito, T.; Isogami, Y.; Miyano, Y.; Mizuno, Y.; Tomimatsu, K.; Hamamura, K.; Takatani, M.; Wakimasu, M. Tetrahedron 2002, 58, 489.
10. (a) Turner, J. A. J. Org. Chem. 1990, 55, 4744.
11. Fenlon, E. E.; Murray, T. J.; Baloga, M. H.; Zimmerman, S. C. J. Org. Chem. 1993, 58, 6625.
12. Repine, J. T.; Johnson, D. S.; Stuk, T.; White, A. D.; Stier, M. A.; Li, T.; Yang, Z.; Maiti, S. N. Tetrahedron Lett. 2007, 48, 8189.
13. Maehr, H.; Smallheer, J. M. J. Org. Chem. 1981, 46, 1752.
14. Warner, P.; Barker, A. J.; Jackman, A. L.; Burrows, K. D.; Roberts, N.; Bishop, J. A. M.; O'Connor, B. M.; Hughes, L. R. J. Med. Chem. 1992, 35, 2761.
15. (a) Speziale, A. J.; Smith, L. R. J. Org. Chem. 1963, 28, 1805.
16. Ramirez, F.; Telefus, C. D. J. Org. Chem. 1969, 34, 376.
17. Sørensen, U. S.; Bleisch, T. J.; Kingston, A. E.; Wright, R. A.; Johnson, B. G.; Schoepp, D. D.; Ornstein, P. L. Bioorg. Med. Chem. 2003, 11, 197.
18. Frigerio, M.; Santagostino, M. Tetrahedron Lett. 1994, 35, 8019.
19. Denmark, S. E.; Fu, J. Org. Lett. 2002, 4, 1951.
20. Magano, J.; Akin, A.; Chen, M. H.; Giza, K.; Moon, J.; Saenz, J. Synth. Commun. 2008, 38, 3631.
21. For an example on the risks of thermal runaway reactions using the NaH/DMF combination see: DeWall, G. Chem. Eng. News 1982, 60, 5.
22. (a) Roush, W. R.; Newcom, J. S. Org. Lett. 2002, 4, 4739.
23. Smith, A. B.; Adams, C. M.; Lodise Barbosa, S. A.; Degnan, A. P. J. Am. Chem. Soc. 2003, 125, 350.
24. (a) Fang, X.; Bandarage, U. K.; Wang, T.; Schroeder, J. D.; Garvey, D. S. J. Org. Chem. 2001, 66, 4019.
25. Semmelhack, M. F.; Jiang, Y.; Ho, D. Org. Lett. 2001, 3, 2403.
26. van Dijk, J. T. M.; Hartwijk, A.; Bleeker, A. C.; Lugtenburg, J.; Cornelisse, J. J. Org. Chem. 1996, 61, 1136.
27. Frejd, T.; Klingstedt, T. Synthesis 1987, 40.
28. (a) Hoffman, J. M.; Wai, J. S.; Thomas, C. M.; Levin, R. B.; O'Brien, J. A.; Goldman, M. E. J. Med. Chem. 1992, 35, 3784.
29. Mogilaiah, K.; Rao, R. B. Synth. Commun. 2002, 32, 747.
30. Diaminopyridine was purchased from Sigma-Aldrich Co. and Lancaster.
31. Bergeron, S.; Chaplin, D. A.; Edwards, J. H.; Ellis, B. S. W.; Hill, C. L.; Holt-Tiffin, K.; Knight, J. R.; Mahoney, T.; Osborne, A. P.; Ruecroft, G. Org. Process Res. Dev. 2006, 10, 661.
32. Ferrarini, P. L.; Biagi, G.; Livi, O.; Primofiore, G.; Carpenè, M. J. Heterocycl. Chem. 1981, 18, 1007.
33. (a) Fuhrer, W.; Gschwend, H. W. J. Org. Chem. 1979, 44, 1133.
34. Adelstein, G. W.; Yen, C. H.; Haack, R. A.; Yu, S.; Gullikson, G.; Price, D. V.; Anglin, C.; Decktor, D. L.; Tsai, H.; Keith, R. H. J. Med. Chem. 1988, 31, 1215.
35. Conley, R. A.; Barton, D. L.; Stefanick, S. M.; Lam, M. M.; Lindabery, G. C.; Kasulanis, C. F.; Cesco-Cancian, S.; Currey, S.; Fabian, A. C.; Levine, S. D. J. Heterocycl. Chem. 1995, 32, 761.
36. U' beda, J. I.; Villacampa, M.; Avendaño, C. Synthesis 1998, 1176.
37. (a) Wünsch, B. Arch. Pharm. 1990, 323, 493.
38. Harvey, R. G.; Dai, Q.; Ran, C.; Penning, T. M. J. Org. Chem. 2004, 69, 2024.
39. Garci'ia- Ruano, J. L.; Alema'n, J.; Aranda, M. T.; Ferna'ndez- Iba'ñez, M. A.; Rodri'guez-Ferna'ndez, M. M.; Maestro, M. C. Tetrahedron 2004, 60, 10067.
40. The chromatographic purification conditions were as follows: Column: Hipersep 600 LP with an internal diameter of 60 cm. Stationary phase: Merck flash silica (63-200 μm, 80 kg). Mobile phase: 4:1 heptane/ethyl acetate, with a flow rate of 3 L/min (nitrogen pressure). UV detection wavelength: 335 nm. Polar impurities were removed in the first injection, and the fractions that contained early eluting impurities and desired product were concentrated. A solvent exchange into toluene was performed to give, after concentration, a final volume of 20 L. The column was back washed with 3 volumes of acetone and, after re-equilibration with 4:1 heptane/ethyl acetate, the 20 L from the first injection was divided into two portions and passed through the column with an acetone back wash with re-equilibration in between.
41. Spangler, R. J.; Boop, D. C.; Kim, J. H. J. Org. Chem. 1974, 39, 1368.
42. Hiremathm, S. P.; Badami, P. S.; Purohit, M. G. Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. 1985, 24B, 1115.
43. Bauvois, B.; Puiffe, M.-L.; Bongui, J.-B.; Paillat, S.; Monneret, C.; Dauzonne, D. J. Med. Chem. 2003, 46, 3900.
44. Mayer, P.; Brunel, P.; Chaplain, C.; Piedecoq, C.; Calmel, F.; Schambel, P.; Chopin, P.; Wurch, T.; Pauwels, P. J.; Marien, M.; Vidaluc, J.-L.; Imbert, T. J. Med. Chem. 2000, 43, 3653.
45. Ganguly, A. K.; Wang, C. H.; Biswas, W. D.; Misiaszek, J.; Micula, A. Tetrahedron Lett. 2006, 47, 5539.
46. For some recent examples on the use of trichloroacetyl isocyanate for the synthesis of ureas, see: (a) Pietsch, M.; Gütschow, M. J. Med. Chem. 2005, 48, 8270.
47. Nishiyama, T.; Isobe, M.; Ichikawa, Y. Angew. Chem., Int. Ed. 2005, 44, 4372.
48. Hanessian, S.; Marcotte, S.; Machaalani, R.; Huang, G.; Pierron, J.; Loiseleur, O. Tetrahedron 2006, 62, 5201.
49. Nudelman, A.; Bechor, Y.; Falb, E.; Fischer, B.; Wexler, B. A.; Nudelman, A. Synth. Commun. 1998, 28, 471.
50. At this point it is unknown whether this intermediate is present in solution as the aldehyde species or as a cyclic aminal. Additional studies with techniques such as ReactIR would be necessary to clarify this point.
51. Hayakawa, M.; Kaizawa, H.; Kawaguchi, K.; Ishikawa, N.; Koizumi, T.; Ohishi, T.; Yamano, M.; Okada, M.; Ohta, M.; Tsukamoto, S.; Raynaud, F. I.; Waterfield, M. D.; Parker, P.; Workman, P. Bioorg. Med. Chem. 2007, 15, 403.
52. Dugave, C.; Kessler, P. Tetrahedron Lett. 1994, 35, 9557.
53. (a) Cardew, P. T.; Davey, R. J. Proc. R. Soc. London, Ser. A 1985, 398, 415.
54. Rodríguez-Hornedo, N.; Murphy, D. J. Pharm. Sci. 1999, 88, 651.
55. Gu, C.; Young, V.; Grant, D. J. W. J. Pharm. Sci. 2001, 90, 1878.
56. Miller, J. M.; Collman, B. M.; Greene, L. R.; Grant, D. J. W.; Blackburn, A. Pharm. Dev. Technol. 2005, 10, 291.
57. Gong, Y.; Collman, B. M.; Mehrens, S. M.; Lu, E.; Miller, J. M.; Blackburn, A.; Grant, D. J. W. J. Pharm. Sci. 2008, 97, 2130.
58. The term "mmol" is used in a broad sense in the literature to represent the minimum solubility needed to ensure confidence in stable form screening, and it refers to millimol/L. It assures that a certain number of molecules go into solution rather than a mass.
59. (a) Grant, D. J. W.; Higuchi, T. Solubility Behavior of Organic Compounds; Wiley: New York, 1990.
60. Ghosh, S.; Grant, D. J. W. Int. J. Pharm. 1995, 114, 185.
61. Zhu, H.; Yuen, C.; Grant, D. J. W. Int. J. Pharm. 1996, 135, 151.
62. Zhu, H.; Grant, D. J. W. Int. J. Pharm. 1996, 139, 33.